Product Description: EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses[1][2][3].
Applications: COVID-19-anti-virus
Formula: C9H11FN2O6
References: [1]Sourimant J, et al. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 2022 Jan 14;375(6577):161-167. /[2]Abas AH, et al. 4’-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review [version 1; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2022, 11:410. /[3]George R. Painter, et al. 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. Patent WO2019173602A1.
CAS Number: 1613589-24-4
Molecular Weight: 262.19
Compound Purity: 99.85
Research Area: Infection
Solubility: DMSO : 25 mg/mL (ultrasonic)/H2O : 35 mg/mL (ultrasonic)
Target: HCV;RSV;SARS-CoV
English
Deutsch
